Effect of Modified Liu Junzitang and Erchentang on Hcy， NO， hs-CRP in Patients with Coronary Heart Disease

Fang HU; Jin-feng SHEN; Zhong-yong LIU

doi:10.13422/j.cnki.syfjx.20201723

您当前的位置：

首页 >

文章列表页 >

Effect of Modified Liu Junzitang and Erchentang on Hcy， NO， hs-CRP in Patients with Coronary Heart Disease

Classic Prescriptions | 更新时间：2020-09-09

- Effect of Modified Liu Junzitang and Erchentang on Hcy， NO， hs-CRP in Patients with Coronary Heart Disease
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 18, Pages: 24-29(2020)
- 作者机构：
  
  1.江西中医药大学，南昌 330006
  2.温岭市第一人民医院，浙江温岭 317500
  3.江西中医药大学附属医院，南昌 330006
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201723
  CLC： R22;R242;R2-031;R287
- Received：01 December 2019，
  
  Published Online：20 July 2020，
  
  Published：20 September 2020
- 稿件说明：
移动端阅览
胡芳,沈金峰,刘中勇.六君子汤合二陈汤加减对冠心病患者Hcy，NO，hs-CRP的影响[J].中国实验方剂学杂志,2020,26(18):24-29.

HU Fang,SHEN Jin-feng,LIU Zhong-yong.Effect of Modified Liu Junzitang and Erchentang on Hcy， NO， hs-CRP in Patients with Coronary Heart Disease[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(18):24-29.
胡芳,沈金峰,刘中勇.六君子汤合二陈汤加减对冠心病患者Hcy，NO，hs-CRP的影响[J].中国实验方剂学杂志,2020,26(18):24-29. DOI： 10.13422/j.cnki.syfjx.20201723.

HU Fang,SHEN Jin-feng,LIU Zhong-yong.Effect of Modified Liu Junzitang and Erchentang on Hcy， NO， hs-CRP in Patients with Coronary Heart Disease[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(18):24-29. DOI： 10.13422/j.cnki.syfjx.20201723.

摘要

目的

通过观察血清同型半胱氨酸（homocysteine，Hcy），一氧化氮（nitric oxide，NO），高敏-C反应蛋白（high-sensitivity C-reactive protein，hs-CRP）与冠脉病变数量及程度的关系及其运用六君子汤联合二陈汤加减对冠心病（coronary heart disease，CHD）患者Hcy，NO，hs-CRP的影响，探讨六君子汤联合二陈汤加减对CHD患者的保护作用。

方法

选取来自江西中医药大学附属医院2016年11月至2019年4月心血管科住院CHD（痰浊内阻型）患者76例，分析Hcy，NO，hs-CRP与冠脉病变数量及程度的关系。以抽签方式，将76例患者随机分为观察组和对照组，每组各38例患者。对照组患者给予常规治疗，观察组患者在常规治疗基础上服用六君子汤合二陈汤加减，周期为3个月。评估两组服药前后中医症状评分；检测两组患者服药前后Hcy，NO，hs-CRP，甘油三酯（TG），低密度脂蛋白（LDL），高密度脂蛋白（HDL），总胆固醇（TC），载脂蛋白A1（Apo A1），载脂蛋白B（Apo B），

末端B型利钠肽原（NT-proBNP），左心室射血分数（LVEF）指标。

结果

Hcy，hs-CRP水平与冠脉病变支数及程度呈正相关。NO水平与冠脉病变支数及程度负相关关系。与本组治疗前比较，两组患者治疗后中医症状评分均有不同程度下降（

0.05）；与对照组治疗后比较，观察组在降低中医症状评分更明显（

0.05）。与本组治疗前比较，两组治疗后可以降低Hcy，hs-CRP水平，提高NO水平（

0.05）；与对照组治疗后比较，观察组降低Hcy，hs-CRP水平及提高NO水平更明显（

0.05）。与本组治疗前比较，两组治疗后均降低TG，LDL，TC，Apo A1，Apo B水平，提高HDL水平（

0.05）；与对照组治疗后比较，观察组可降低TG，LDL，TC，Apo A1，Apo B水平，提高HDL水平（

0.05）。与本组治疗前比较，两组治疗后均可提高LVEF水平，降低NT-proBNP水平（

0.05）；与对照组治疗后比较，观察组可提高LVEF水平，降低NT-proBNP水平（

0.05）。

结论

Hcy，hs-CRP水平与冠脉病变呈正相关关系，NO水平与冠脉病变呈负相关，六君子汤联合二陈汤加减可能是通过抑制CHD患者的Hcy，hs-CRP及提高CHD患者的NO水平，从而降低患者血脂，提高患者心功能，改善患者临床症状。

Abstract

Objective

To observe the relationship between serum homocysteine (Hcy)

nitric oxide (NO)

high-sensitivity C-reactive protein (hs-CRP) as well as the number and degree of coronary lesions

and the effect of Liu Junzitang combined with Erchentang on Hcy

hs-CRP in patients with coronary heart disease (CHD)

so as to explore the protector effect of Liu Junzitang combined with Erchentang on CHD patients.

Method

A total of 76 inpatients with phlegm turbidity and internal resistance (CHD) from the Cardiovascular Department of Jiangxi University of Traditional Chinese Medicine（TCM） from November 2016 to April 2019 were selected to analyze the relationship between Hcy

hs-CRP as well as the number and degree of coronary lesions. By lottery

the 76 patients were randomly divided into observation group and control group

with 38 patients in each group. Patients in the control group were given conventional therapy

while patients in the observation group were given Liu Junzitang combined with Erchentang in addition to conventional therapy. The experimental period was 3 months. TCM symptom scores of the two groups before and after administration were evaluated. Hcy

hs-CRP

triglyceride (TG)

low-density lipoprotein (LDL)

high-density lipoprotein (HDL)

and total cholesterol (TC)

apolipoprotein A1 (Apo A1)

apolipoprotein B (Apo B)

-terminal B-type natriuretic peptide (NT-proBNP)

left ventricular ejection fraction (LVEF) indicators of the two groups were measured before and after administration.

Result

The levels of Hcy and hs-CRP were positively correlated with the number and degree of coronary lesions. The level of NO was negatively correlated with the number and degree of coronary lesions. TCM symptom scores were different between the two groups after treatment. Compared with the control group

the TCM symptom score in the observation group was decreased more significantly (

0.05). The two groups could reduce Hcy

hs-CRP and increase in NO to a certain extent (

0.05). Compared with the control group

the observation group showed reduction in Hcy

hs-CRP and increase in NO more significantly (

0.05). After treatment in both groups

LDL

Apo A1

Apo B and HDL were reduced (

0.05) compared with before treatment. Compared with the control group

the observation group showed decrease in TG

LDL

Apo A1

Apo B and increase in HDL more significantly (

0.05). Both groups could increase LVEF and decrease NT-proBNP after treatment (

0.05). Compared with the control group

the observation group increased LVEF and decreased NT-proBNP more significantly (

0.05).

Conclusion

The levels of Hcy and hs-CRP were positively correlated with coronary lesions

while the level of NO was negatively correlated with coronary lesions. Modified Liu Junzitang and Erchentang may be correlated with inhibition of Hcy

hs-CRP and CHD and increase of patient's NO level

thereby reducing the patient's blood lipids

improving the patient's heart function

and improving the patient's clinical symptoms.

关键词

Keywords

references

刘卫花 , 王家艳 , 燕垚旬 , 等 . 血尿酸及血脂检测应用于老年冠心病合并脑梗死患者的临床价值 [J]. 中国老年学杂志 , 2019 , 39 ( 15 ): 3605 - 3608 .

赵爱梅 , 任钧国 , 刘建勋 . 益气活血方治疗冠心病气虚血瘀证作用机制研究进展 [J]. 中国实验方剂学杂志 , 2017 , 23 ( 7 ): 215 - 220 .

刘亚荣 . 阿托伐他汀联合降脂灵胶囊治疗冠心病高血脂症疗效及对血脂、血管内皮功能、心脏功能的影响 [J]. 现代中西医结合杂志， 2019 ， 28 （ 22 ）： 2464 - 2466，2488 .

刘晓宁 . 瑞舒伐他汀对冠心病合并高脂血症患者炎症因子与内皮功能的影响 [J]. 航空航天医学杂志 , 2019 ， 30 ( 7 ): 840 - 841 .

邹云法 , 余文华 , 徐丽君 , 等 . NO、ET-1、Hcy联合检测在冠心病中的诊断价值 [J]. 中华全科医学 , 2019 , 17 ( 7 ): 1178 - 1180 .

李镇 , 邵名亮 , 胡龙 , 等 . 血清同型半胱氨酸及载脂蛋白A-Ⅰ水平与冠心病的关联分析 [J]. 安徽医药 , 2019 , 23 ( 8 ): 1543 - 1546 .

易帆 , 曾召琼 , 李萍 , 等 . 同型半胱氨酸在冠心病发病机制中的研究进展 [J]. 国际检验医学杂志 , 2019 , 40 ( 11 ): 1365 - 1368 .

李冬玉 . 药食心葆汤对心血瘀阻证冠心病患者血清同型半胱氨酸及凝血功能的影响 [J]. 中国实验方剂学杂志 , 2017 , 23 ( 12 ): 178 - 181 .

贺俊波 , 刘华东 , 陈科奇 , 等 . 降同型半胱氨酸疗法对冠心病介入治疗后患者炎症反应的影响 [J]. 现代电生理学杂志 , 2019 , 26 ( 2 ): 95 - 99 .

李翠萍 . 冠心病与同型半胱氨酸的相关性探讨 [J]. 中国冶金工业医学杂志 , 2019 , 36 ( 3 ): 308 - 309 .

陈文娜 , 朱爱松 , 丛培玮 , 等 . 基于网络药理学的二陈汤治疗冠心病分子机制研究 [J]. 中草药 , 2019 , 50 ( 2 ): 441 - 448 .

邝唯铭 , 魏峥 . 二陈汤联合盐酸曲美他嗪片治疗痰阻心脉型心绞痛的疗效及对血清纤维蛋白原及 D -二聚体的影响 [J]. 中国药业 , 2018 , 27 ( 5 ): 36 - 38 .

郑丽莉 . 芎归六君子汤对大鼠急性心肌梗死的治疗作用 [J]. 中国中医基础医学杂志 , 2018 , 24 ( 6 ): 760 - 762，788 .

WRIGHT R S , ANDERSON J L , ADAMS C D , et al . 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction:a report of the American college of cardiology foundation/American heart association task force on practice guidelines developed in collaboration with of the American academy of family physicians, society for cardiovascular angiography and interventions, and the society of thoracic surgeons [J]. J Am Coll Cardiol , 2011 , 57 ( 19 ): 215 - 367 .

黄晖 , 严宁 , 王义勇 , 等 . 冠心病患者血浆同型半胱氨酸水平与冠状动脉病变SYNTAX积分的相关性研究 [J]. 中国全科医学 , 2017 , 20 ( 10 ): 1208 - 1213，1224 .

田德禄 . 中医内科学 [M]. 上海：上海科学技术出版社 , 2013 : 126 - 133 .

中华人民共和国卫生部 . 中药新药临床研究指导原则 [M]. 北京：中国医药科技出版社 , 2002 : 157 - 162 .

耿运玲 , 吴圣贤 , 马媛媛 , 等 . 试述寒气生浊 [J]. 中医杂志 , 2019 , 60 ( 14 ): 1181 - 1184 .

何伟 . 构建中医浊邪理论体系框架的初步探讨 [J]. 中医杂志 , 2015 , 56 ( 21 ): 1801 - 1803 .

石锐 , 常立萍 , 王国强 , 等 . 冠心病证候要素分析及伏邪与冠脉病变程度相关性研究 [J]. 中国中医急症 , 2019 , 28 ( 3 ): 435 - 437 .

许慧愚 , 王朔 , 邓兵 , 等 . 冠心病稳定型心绞痛痰瘀互结证中医证候量表与生化指标相关性 [J]. 中华中医药杂志 , 2019 , 34 ( 4 ): 1457 - 1461 .

王阶 , 邢雁伟 , 姚魁武 , 等 . 冠心病“痰瘀滞虚”理论内涵与外延 [J]. 中医杂志 , 2019 , 60 ( 4 ): 280 - 284 .

王传池 , 杨燕 , 吴珊 , 等 . 冠心病不同发展阶段中医证演变规律研究 [J]. 中华中医药杂志 , 2019 , 34 ( 5 ): 2101 - 2106 .

李海燕 , 陈磊 , 汤杰 , 等 . 浊邪致病及论治初探 [J]. 上海中医药大学学报 , 2015 , 29 ( 5 ): 19 - 23 .

罗嗣卿 , 杨红梅 , 陈豫 , 等 . 健脾化浊调脂颗粒临床应用举隅 [J]. 江西中医药 , 2015 , 46 ( 9 ): 37 - 38 .

徐飞 , 刘中勇 . 刘中勇治疗颈动脉斑块经验 [J]. 江西中医药 , 2019 , 50 ( 7 ): 20 - 22 .

郑丽莉 . 芎归六君子汤对大鼠急性心肌梗死的治疗作用 [J]. 中国中医基础医学杂志 , 2018 , 24 ( 6 ): 760 - 762，788 .

张秀洲 , 刘福艳 , 李静 , 等 . 血管内皮功能和同型半胱氨酸对老年冠心病患者发病的相关性探讨 [J]. 中华老年心脑血管病杂志 , 2015 , 17 ( 12 ): 1268 - 1270 .

Homocysteine Studies Collaboration . Homocysteine and risk of ischemic heart diease and stroke: a Meta analysis [J]. JAMA , 2002 , 288 ( 16 ): 2015 - 2022 .

陈国强 , 巫剑雄 , 陈宣龙 , 等 . 冠心病患者血清同型半胱氨酸和超敏C反应蛋白水平与冠状动脉病变的相关性 [J]. 广东医科大学学报 , 2019 , 37 ( 4 ): 461 - 463 .

张志敏 , 赵连友 , 邹青 , 等 . 依那普利叶酸片对高血压伴高同型半胱氨酸血症大鼠左室肥厚干预的研究 [J]. 现代生物医学进展 , 2014 , 14 （ 13 ）: 2417 - 2421 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment and Evaluation of Rat Model of Myocardial Ischemia-reperfusion Injury with Phlegm and Blood Stasis Blocking Collaterals Syndrome Based on Metabolomics

Establishment and Evaluation of Rat Model of Acute Myocardial Infarction in Coronary Heart Disease with Qi and Yin Deficiency Syndrome Based on Sleep Deprivation Combined with Coronary Artery Ligation

Mechanism of Xuefu Zhuyutang in Intervening in Ferroptosis in Rats with Coronary Heart Disease with Blood Stasis Syndrome Based on ACSL4 Signalling Pathway

Construction of an Intelligent Diagnosis and Treatment Ontology for Traditional Chinese Medicine Based on Clinical Practice Guidelines：A Case Study of Coronary Heart Disease

Effect of Yiqi Huoxue Prescription on cAMP/Epac1/Rap1 Signaling Pathway in Coronary Heart Disease Rats with Qi Deficiency and Blood Stasis Syndrome

Related Author

HU Longxiao

GAO Jiabei

MA Weihao

LU Jieming

GAO Yunxiao

YUAN Yue

ZHANG Qiuyan

CHEN Xiaoxiao

Related Institution

School of Clinical Medicine，Beijing University of Chinese Medicine

Beijing Key Laboratory of Chinese Materia Pharmacology，National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases，Institute of Basic Medical Sciences， Xiyuan Hospital，China Academy of Chinese Medical Sciences

Natural History Museum of China

Institute of Basic Medical Sciences，Xiyuan Hospital，China Academy of Chinese Medical Sciences

Hunan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰